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Genetic and pharmacological 
inhibition of vanin-1 activity in 
animal models of type 2 diabetes
Janna A. van Diepen1, Patrick A. Jansen2, Dov B. Ballak1, Anneke Hijmans1, 
Floris P.J.T. Rutjes3, Cees J. Tack1, Mihai G. Netea1, Joost Schalkwijk2 & Rinke Stienstra1,4
Vanins are enzymes that convert pantetheine to pantothenic acid (vitamin B5). Insights into the 
function of vanins have evolved lately, indicating vanin-1 to play a role in inflammation, oxidative 
stress and cell migration. Moreover, vanin-1 has recently gained attention as a novel modulator of 
hepatic glucose and lipid metabolism. In the present study, we investigated the role of vanin-1 in the 
development of hepatic steatosis and insulin resistance in animal models of obesity and diabetes. 
In addition, we evaluated the potency of RR6, a novel pharmacological vanin-1 inhibitor, as an anti-
diabetic drug. Increased vanin activity was observed in plasma and liver of high fat diet (HFD)-induced 
obese mice, as well as ZDF-diabetic rats. Ablation of vanin-1 (Vnn1−/− mice) mildly improved glucose 
tolerance and insulin sensitivity in HFD-fed mice, but had no effects on body weight, hepatic steatosis 
or circulating lipid levels. Oral administration of RR6 for 8 days completely inhibited plasma vanin 
activity, but did not affect hepatic glucose production, insulin sensitivity or hepatic steatosis in ZDF-
diabetes rats. In conclusion, absence of vanin-1 activity improves insulin sensitivity in HFD-fed animals, 
yet short-term inhibition of vanin activity may have limited value as an anti-diabetic strategy.
Disturbances of hepatic glucose and lipid metabolism play an important role in the development of insulin resist-
ance and type 2 diabetes. Vanin-1 has recently gained interest as a novel modulator of hepatic glucose- and lipid 
metabolism, and has been suggested as a potential target to treat metabolic diseases1,2. Vanin-1 is an enzyme 
with pantetheinase activity, which catalyzes the hydrolysis of pantetheine into pantothenic acid (vitamin B5) and 
cysteamine3,4. Vanin-1 is member of a larger vanin family, consisting of three human (VNN1, VNN2 and VNN3) 
and two mouse (Vnn1 and Vnn3) orthologous genes5. Although vanins are poorly characterized at the functional 
level, insights into the function of vanin-1 have evolved lately, largely due to generation of the Vnn1-deficient 
mouse6. So far, vanins have been indicated to play a role in inflammation, oxidative stress and cell migration7–9, 
processes that are thought to be mediated via vanin-dependent cysteamine production10.
In addition, several recent studies have elucidated a role for vanin-1 in the regulation of key metabolic path-
ways. Expression of vanin-1 is high in liver and strongly induced by fasting, as one of the most prominently 
regulated genes by PPARα 1,11. Moreover, after prolonged fasting, inhibition of vanin activity aggravates hepatic 
steatosis1. Interestingly, increased vanin-1 expression has recently also been observed in murine steatotic livers 
during obesity12,13. Whether inhibition of vanin activity is causally involved in the development of steatosis during 
obesity remains unknown.
In addition to hepatic lipid metabolism, vanin-1 was recently shown to modulate glucose metabolism by 
directly enhancing hepatic glucose output2. These observations point towards vanin-1 inhibition as a potential 
novel pharmacological target to treat metabolic diseases with enhanced glucose production, such as diabetes.
In the current study we set out to study the effect of vanin-1 deficiency on the development of obesity-induced 
hepatic steatosis and diabetes, as well as the potency of RR6, a novel pantetheinase (vanin) inhibitor, as an 
anti-diabetic drug using experimental animal models.
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Results
The presence of obesity and insulin resistance promotes vanin activity in animal models. The 
levels of vanin activity were evaluated in HFD-induced obese (DIO) mice as well as ZDF-diabetes rats. Both 
hepatic vanin-1 mRNA (Fig. 1A) and plasma vanin activity (Fig. 1B) were increased in DIO mice as compared to 
the LFD-fed lean controls. Similarly, ZDF-diabetes rats displayed augmented hepatic vanin-1 mRNA expression 
(Fig. 1C) and increased plasma vanin activity (Fig. 1D) as compared to lean controls. In contrast to vanin-1, 
expression of vanin-3 was only mildly upregulated in obese, insulin-resistant mice and rats (Supplementary Fig. 
S1A,B).
Metabolic effects of diet-induced obesity in vanin-1 knockout mice. Plasma vanin activity 
was strongly reduced in Vnn-1−/− mice (− 93%; Fig. 1B). To study the causal relation between vanin-1 and 
obesity-related metabolic disturbances, Vnn-1−/− and WT mice were fed 16 weeks high-fat diet (45% kcal, HFD) 
or a control low-fat diet (10% kcal, LFD). HFD-feeding induced a similar bodyweight in both Vnn-1−/− and WT 
mice (Fig. 2A), and food intake was not different between both genotypes (Supplementary Fig. S2A). In addition, 
plasma cholesterol and free fatty acid (FFA) levels were increased upon HFD-feeding, but not affected by vanin-1 
deficiency (Fig. 2B,C). Plasma TG did not differ between groups (Fig. 2D). Recent studies, as well as our data, 
show a strong increase in vanin-1 expression in murine steatotic livers (Fig. 1)12,13, prompting to hypothesize a 
causal role for vanin-1 in the progression of steatosis13. However, we show that hepatic steatosis as reflected by 
hepatic TG levels (Fig. 2E) and HE staining (Fig. 2F) was not affected by vanin-1 deficiency in LFD- or HFD-fed 
mice.
The absence of vanin-1 mildly improves insulin sensitivity in obese, insulin resistant 
mice. Subsequently, we evaluated the role of vanin-1 in obesity-induced disturbances in glucose metabolism. 
Therefore, LFD- and HFD-fed Vnn-1−/− and WT mice were subjected to an oral glucose tolerance test (OGTT) 
and insulin tolerance test (ITT). Absence of vanin-1 neither affected plasma glucose nor insulin levels in mice 
fed a LFD or HFD (Fig. 3A,B). Upon LFD-feeding, no difference was observed between Vnn-1−/− mice and WT 
Figure 1. Obesity and insulin resistance increases vanin activity. Vnn-1−/− and wild type (WT) mice were fed 
low fat diet (LFD) or high fat diet (HFD) for 16 weeks. Depicted are: (A) relative hepatic mRNA levels of Vnn1 
and (B) plasma vanin activity. Data are mean ± SD from n = 7–9 animals per group. Lean and ZDF rats were 
treated with the vanin inhibitor RR6. (C) Relative hepatic mRNA levels of Vnn1 and (D) plasma vanin activity 
were determined. Data are mean ± SD from n = 5 animals per group. *p < 0.05, ** P < 0.01, *** P < 0.001.
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mice regarding glucose tolerance (Fig. 3C) or insulin sensitivity (Fig. 3D). Upon HFD-feeding, however, Vnn-
1−/− mice had a slightly faster glucose clearance as compared to WT littermates, as reflected by lower glucose 
levels 2h after an oral glucose load (Fig. 3E). In addition, insulin injection induced a faster drop in glucose levels 
in Vnn-1−/− versus WT mice fed a HFD (Fig. 3F). Despite the slightly faster insulin-induced clearance of glu-
cose, total area under the curves for OGTT and ITT were not different between HFD-fed Vnn1−/− and WT mice 
(Fig. 3G,H). These data suggest that a reduction in vanin activity mildly improved insulin sensitivity in an obese, 
insulin-resistant mouse model.
Absence of vanin-1 has been shown to reduce inflammation and oxidative stress during infection of injury14,15. 
Since these pathways are known to contribute to insulin resistance, expression of markers of inflammation and 
oxidative stress in liver and adipose tissue were determined (Supplementary Fig. S3). High-fat feeding similarly 
increased expression of F4/80, Clec7a and Tnfα in adipose tissue of Vnn1−/− and WT mice (Supplementary Fig. 
S3A–C), accompanied by a similar reduction in Glut4 expression (Supplementary Fig. S3D), suggestive of compa-
rable levels of inflammation and insulin resistance in adipose tissue in both genotypes. Similarly in liver, Vanin-1 
deficiency did not affect expression of genes involved in inflammation (F4/80, Clec7a, IL-1b; Supplementary Fig. 
Figure 2. Plasma lipids and hepatic steatosis in diet-induced obese vanin-1 knockout mice. Vnn-1−/− and 
wild type (WT) mice were fed low fat diet (LFD) or high fat diet (HFD) feeding for 16 weeks. (A) Bodyweight 
development and non-fasted (B) plasma free fatty acids, (C) plasma cholesterol, (D) plasma triglycerides (TG), 
(E) hepatic triglyceride [TG] content and (D) H&E staining of liver sections; magnification 200× . Data are 
mean ± SD from n = 7–9 animals per group. *p < 0.05, ** P < 0.01.
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Figure 3. The absence of vanin-1 mildly improves insulin sensitivity in obese, insulin resistant mice.  
Vnn-1−/− and wild type (WT) mice were fed low fat diet (LFD) or high fat diet (HFD) feeding for 16 weeks.  
(A) 9h Fasted blood glucose and (B) non-fasted plasma insulin levels after 16 weeks of LFD or HFD. Blood 
glucose levels of LFD-fed mice during (C) oral glucose tolerance test (OGTT) and (D) insulin tolerance test 
(ITT), as well as HFD-fed mice during (E) OGTT and (F) ITT. Area under the curve (AUC) during OGTT  
(G) and ITT (H). Data are mean ± SD from n = 7–9 animals per group. *p < 0.05.
www.nature.com/scientificreports/
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S3E–G) or oxidative stress (Gss, Gpx1, Gclm; Supplementary Fig. S3H–J). Thus, the mild improvement in insulin 
sensitivity in HFD-fed Vnn1−/− is not associated with apparent changes in inflammation or oxidative stress in 
liver or adipose tissue.
The effect of pharmacological inhibition of vanin activity in ZDF-diabetes rats. We subsequently 
evaluated whether RR6, a recently developed competitive inhibitor of vanin activity16, would improve insulin 
sensitivity in an animal model for diabetes.
RR6 supplementation in drinking water is a potent inhibitor of vanin activity in rats16, almost completely 
inhibiting plasma vanin activity (Fig. 1D and Supplemental Fig. S4). In contrast in mice, no complete inhibi-
tion of vanin activity is obtained by RR6 administration (max 75%; Supplemental Fig. S4) due to a very fast 
clearance (half life approx. 80 min). Since no complete vanin inhibition could be achieved in mice, we used the 
ZDF-diabetes rats as an animal model for diabetes to evaluate the effects of RR6 on hepatic steatosis and insulin 
sensitivity.
Treatment of ZDF-diabetes rats with RR6 for 8 days led to an almost complete inhibition of plasma vanin 
activity (− 98%; Fig. 1D). Similar to mice, inhibition of vanin activity did not affect bodyweight (Fig. 4A), food 
intake (Supplementary Fig. S2B) or hepatic steatosis as measured by TG levels (Fig. 4B), supported by similar 
expression of hepatic PPARγ (Supplementary Fig. S5A,D). In addition, vanin inhibition did not affect plasma lev-
els of TG, total cholesterol or FFA levels (Supplementary Fig. S6A–C). In contrast to the results obtained in mice, 
we found no effect of vanin-inhibition on insulin sensitivity in ZDF-diabetes rats (Fig. 4C). It has recently been 
shown that inhibition of vanin-1 with siRNA reduces expression of genes involved in hepatic gluconeogenesis and 
reduces fasting plasma glucose levels2. Therefore, to determine whether vanin inhibition by RR6 affects hepatic 
Figure 4. The effect of pharmacological inhibition of vanin activity in ZDF-diabetes rats. ZDF rats were 
administered with the vanin inhibitor RR6 in drinking water for 8 days. Depicted are (A) bodyweight,  
(B) hepatic triglyceride [TG] content and blood glucose levels during (C) ITT and (D) pyruvate tolerance test 
(PTT). Data are mean ± SEM from n = 5 animals per group.
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gluconeogenesis in obese, diabetic rats, we performed a pyruvate tolerance test, which allows for quantification 
of gluconeogensis. Inhibition of vanin activity did not affect fasting glucose levels, or hepatic glucose production 
during a pyruvate test (Fig. 4D). In accordance, vanin-1 deficiency in mice or inhibition of vanin activity in rats 
did not affect hepatic expression of the gluconeogenic genes Pepck or G6pase (Supplementary Fig. S5).
Discussion
Vanin-1 is known as a pantetheinase, catalyzing the hydrolysis of pantetheine into pantothenic acid and cysteam-
ine. In addition, vanin-1 recently emerged as one of the most prominent genes regulated by PPARα 1,11,17 and is 
proposed to play a role in the regulation of key metabolic pathways10. Especially under fasting conditions, vanin 
activity has been reported to modulate lipid- and glucose metabolism and could be a new therapeutic target in 
metabolic disease1,2,16.
The first objective of the current study was to examine whether absence of vanin-1 or inhibition of vanin 
activity, would affect hepatic steatosis in obese animal models. After prolonged fasting, inhibition of vanin activ-
ity aggravates hepatic steatosis1. In addition, the highly increased vanin-1 expression in murine steatotic liv-
ers12,13, instigated the idea of a causal role for vanin-1 in the progression of steatosis during obesity. However, our 
experiments show that neither genetic absence (Vnn1−/− mice) nor pharmacological inhibition of total vanin 
activity by RR6 affects hepatic steatosis in animal models of obesity. Thus vanin-1 expression appears to prevent 
excessive accumulation of TG in the liver during fasting1, but not in response to HFD-feeding. This suggests 
that the observed increase in vanin-1 expression in steatotic livers of obese mice, may rather be a marker of 
enhanced PPARα activation, without causal involvement of vanin-1 in the progression or prevention of steatosis 
during obesity. Our data show that the increased expression of Vnn1 in steatotic livers concurs with an increase in 
total plasma vanin activity. Therefore, plasma vanin activity could possibly serve as a valuable marker of hepatic 
PPARα activation and/or steatosis in obese subjects. In human subjects, vanin activity has shown to increase in 
response to both prolonged fasting as well as treatment with fibrates, known ligands for PPARα 1. Whether vanin 
activity can serve as a marker for steatosis in obese subjects remains to be established.
The current experiments show that absence of vanin-1 did not affect hepatic expression of genes involved 
in inflammation or oxidative stress in HFD-fed mice. Importantly however, HFD-fed C57Bl/6 mouse and the 
Zucker Diabetic Fatty (ZDF) rat are models to evaluate development of hepatic steatosis, but not development 
of steatohepatitis or hepatic oxidative stress18,19. Therefore, the effect of vanin-1 on these pathological hepatic 
processes needs careful future evaluation in more appropriate experimental settings. The HFD-fed C57Bl/6 
mouse is a suitable mouse model to evaluate development of adipose tissue inflammation during obesity. Indeed, 
HFD-feeding in the current study clearly induced adipose tissue inflammation. Vanin-1 has previously been 
shown to antagonize peroxisome proliferator-activated receptor gamma activity in epithelial cells7. A similar 
mechanism in adipocytes would hypothetically improve adipose tissue function and reduce inflammatory path-
ways. However, our data show that absence of vanin-1 did not affect adipose tissue inflammation or function.
The second objective of the current study was to examine whether absence of vanin-1 or inhibition of vanin 
activity, would improve insulin sensitivity in obese animal models. To this extend, glucose metabolism was inves-
tigated in HFD-fed Vnn-1−/− mice as well as in ZDF rats treated with the novel vanin-inhibitor RR6. Although we 
observed a strong upregulation of hepatic Vnn1 expression and plasma vanin activity in obese, insulin resistant 
mice and rats, our results suggest that vanin-1 only plays a minor role in the pathophysiology of insulin resistance. 
Whereas the complete absence of vanin-1 led to an increase in insulin sensitivity and glucose tolerance after a 
long term HFD-intervention in mice, short-term inhibition of vanin activity had no beneficial effect on insulin 
sensitivity or hepatic glucose production in diabetic rats. These results suggest that the contribution of vanin-1 
to the development of insulin resistance is rather indirect. Another explanation for the differences observed in 
RR6-treated rats and Vnn1−/− mice could possibly be that not vanin activity, but the presence of vanin-1 protein 
may be (mildly) involved in the development of insulin resistance. The recently revealed structure of vanin-1 by 
X-ray crystallography suggests that it could operate both as an enzyme and a signaling protein20. In our ZDF-rats 
model, vanin inhibition did not affect the expression of vanin-1 (Fig. 1C) or vanin-3 (Supplementary Fig. S1B), 
which could thus still function as signaling proteins.
Previous findings show that basal glucose levels and glucose tolerance do not change in Vnn1−/− mice21, which 
is line with our observations in control LFD-fed Vnn1−/− and WT mice. Our findings in HFD-fed mice are partly 
in contrast with Chen et al., who demonstrated increased hepatic glucose production and insulin resistance upon 
activation of vanin-1 using adenovirus vanin-1 (adVnn1), while inhibition of vanin-1 using siRNA against VNN1 
reduced these processes in an obese mouse model2. We did not observe regulation of genes involved in glucone-
ogenesis, such as Pepck or G6pase, in Vnn1−/− animals or after treatment with RR6. Possibly, differences in the 
dietary intervention approach or in the animal models that were used may explain the discrepancies between the 
two studies. Additionally, the effect of liver-specific and short-term (3 days) modulation of vanin-1 activity by 
siRNA done by Chen et al. versus total inhibition of vanin-1 activity in our study may have differential outcomes 
on systemic glycemic control. But most importantly, treatment of db/db mice with siVNN1 reduced their food 
intake by 50% 2, which will largely affect their bodyweight (which were not shown) and contribute to the observed 
reduction in blood glucose levels. Importantly, the improved glucose tolerance and insulin sensitivity induced by 
siVNN1 in their study was largely defined by a significant difference in basal glucose levels, while the change in 
blood glucose levels after insulin or glucose injection were similar2. In our hands, absence of vanin or inhibition 
of vanin activity did not affect food intake. Moreover, for therapeutic possibilities, the current results on pharma-
cological inhibition of vanin activity are likely most relevant.
We did not observe any effect of vanin-1 deficiency on plasma TG, cholesterol or FFA levels in mice upon 
HFD-feeding. Interestingly, pantethine, the stable disulfide of pantetheine and substrate for vanin activity, is 
known as a natural compound with hypolipidemic effects22, which may be mediated by increased cysteamine 
levels23. Importantly, the HFD-fed C57Bl/6 mouse model and ZDF rat models were used to evaluate the effect of 
www.nature.com/scientificreports/
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vanin inhibition on hepatic steatosis and insulin resistance specifically. These animal models are characterized 
by only minor changes in plasma lipid levels upon HFD-feeding. Therefore, to specifically evaluate the effect of 
vanin(-1) inhibition on plasma lipids and lipoprotein metabolism, additional studies need to be performed in 
more suitable hyperlipidemic mouse models such as the ApoE3Leiden or LDLr deficient mouse model.
In conclusion, our findings indicate that absence of vanin-1 only mildly improves insulin sensitivity, whereas 
short-term inhibition of vanin-activity using RR6 has no beneficial effects in obese, insulin resistant animals.
Methods
Animals and RR6 administration. Mice and rats were housed under standard conditions and experiments 
were approved by the institutional ethical committee on animal experimentation of the Radboud University Medical 
Center (Nijmegen) and methods were carried out in accordance with the approved guidelines. Vanin-1 knockout 
mice were generated as described before6 and were backcrossed to a C57Bl/6J background. Male vanin-1−/−  
(Vnn1−/−) mice and wild type (WT) littermates of 12–14 weeks old were given low-fat (LFD) or high-fat diet 
(HFD) diet for 16 weeks, containing 10% or 45% of energy derived from fat, respectively (D12450B or 12451; 
Research Diets, Inc). Male lean Wistar rats and Zucker Diabetic Fatty (ZDF) rats (Harlan) of 8 weeks old were 
treated with the pantetheinase (vanin) inhibitor RR6 (3 mg/mL; dissolved in drinking water16) or vehicle for 
8 days. The pantetheine analogue RR6 acts as a selective and potent vanin inhibitor, which causes an almost 
complete inhibition of all vanin activity in rats16. Mice and rats were sacrificed at the end of the diet- or RR6 
treatment respectively (non-fasted; between 9 am and 11 am) and blood and organs were collected for analysis. 
Pharmacodynamic analysis of RR6 in mice was performed and compared to RR6 pharmacodynamics in rats that 
have been described before16. Shortly, animals (n = 3) were given RR6 by a single oral administration (50 mg/
kg; dissolved in 10% DMSO in PBS). Heparinized blood samples were drawn at several time points after the oral 
gavage and plasma was obtained by centrifugation for determination of plasma vanin activity as described below.
Studies on glucose homeostasis. Oral glucose tolerance (OGTT), insulin tolerance (ITT) and pyruvate 
tolerance tests (PTT) were performed. Prior to the OGTT, animals were fasted overnight (9 hours; 11 pm–8 am) 
after which 2 g/kg glucose (D-glucose, Gibco, Invitrogen) was orally administered. Prior to the ITT and PTT, 
animals were fasted 4 hours (5 am–9 am) and insulin (0.75 U/kg) or pyruvate (1.5 gr/kg) was injected intraperito-
neally. Blood glucose levels were determined with an Accu-chek glucosemeter (Roche Diagnostics, Almere, The 
Netherlands) at stated time points.
Vanin activity assay. Vanin (pantetheinase) activity was determined in plasma as described before16,24. 
Shortly, a buffered pantothenate-7-amino-4-methylcoumarin solution (Pan-AMC; 10 μ M final concentration) 
was evaporated to dryness in 96-well plates before plasma samples were added and incubated for 60 minutes. 
Fluorescence was measured using a luminescence spectrometer (LS55, Perkin Elmer).
Plasma and hepatic lipid analysis. Non-fasted plasma levels of triglycerides (TG), total cholesterol (TC) 
(Liquicolor, Human GmbH, Wiesbaden, Germany) and free fatty acids (FFA; NEFA-C WAKO chemicals, GmbH, 
Neuss Germany) were determined enzymatically according to manufacturer’s instructions. Hepatic TG con-
centrations were measured in 10% liver homogenates using a commercial kit from Liquicolor (Human GmbH, 
Germany) and expressed per mg tissue. For histological examination, H&E staining of sections was done using 
standard protocols on 5 μ m-thick liver sections.
RNA isolation and qPCR analysis. Total RNA was isolated from liver and adipose tissue using TRIzol 
(Invitrogen, Carlsbad, CA), according to manufacturer’s instructions. RNA was reverse transcribed (iScript 
cDNA Synthesis Kit, Bio-Rad Laboratories) and qPCR was performed using Power SYBR green master mix 
(Applied Biosystems, Foster City, CA) using the Step-one Real-Time PCR system (Applied Biosystems). Values 
were corrected using the housekeeping gene 36B4. Primer sequences are listed in Supplemental Table 1.
Statistical analysis. Data are means ± SD unless indicated otherwise. Statistical analyses were performed 
using Graphpad Prism 5.0. Differences between 4-groups were tested with ANOVA with post-hoc Bonferroni 
correction. Comparisons between 2-groups (RR6 vs control) were calculated using a Student t-test. P < 0.05 was 
considered statistically significant.
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